Sensitivity analysis for evaluating principal surrogate endpoints relaxing the equal early clinical risk assumption
From MaRDI portal
Publication:2170431
DOI10.1214/21-AOAS1566zbMath1498.62222WikidataQ114599225 ScholiaQ114599225MaRDI QIDQ2170431
Yingying Zhuang, Ying Huang, Peter B. Gilbert
Publication date: 5 September 2022
Published in: The Annals of Applied Statistics (Search for Journal in Brave)
sensitivity analysiscausal inferenceprincipal stratificationestimated maximum likelihoodprincipal surrogatevaccine efficacy curve
Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50)
Cites Work
- Unnamed Item
- The evaluation of surrogate endpoints.
- Design and Estimation for Evaluating Principal Surrogate Markers in Vaccine Trials
- Statistical Identifiability and the Surrogate Endpoint Problem, with Application to Vaccine Trials
- Principal Stratification in Causal Inference
- Sensitivity Analysis for the Assessment of Causal Vaccine Effects on Viral Load in HIV Vaccine Trials
- Evaluating principal surrogate markers in vaccine trials in the presence of multiphase sampling
- Evaluating Candidate Principal Surrogate Endpoints
- Related Causal Frameworks for Surrogate Outcomes
- Sensitivity Analysis for Incomplete Contingency Tables: The Slovenian Plebiscite Case
- The validation of surrogate endpoints in meta-analyses of randomized experiments
- Augmented Designs to Assess Immune Response in Vaccine Trials
- Sensitivity Analyses Comparing Outcomes Only Existing in a Subset Selected Post‐Randomization, Conditional on Covariates, with Application to HIV Vaccine Trials
- A Generalization of Sampling Without Replacement From a Finite Universe
This page was built for publication: Sensitivity analysis for evaluating principal surrogate endpoints relaxing the equal early clinical risk assumption